Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 57

1.

Targeted therapy of gastrointestinal stromal tumours.

Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D.

World J Gastrointest Surg. 2016 May 27;8(5):345-52. doi: 10.4240/wjgs.v8.i5.345. Review.

2.
3.

Beyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.

Alturkmani HJ, Pessetto ZY, Godwin AK.

Expert Opin Investig Drugs. 2015;24(8):1045-58. doi: 10.1517/13543784.2015.1046594. Epub 2015 Jun 22. Review.

4.

Platelet-Derived Growth Factor Receptor-α Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1.

Hayashi Y, Bardsley MR, Toyomasu Y, Milosavljevic S, Gajdos GB, Choi KM, Reid-Lombardo KM, Kendrick ML, Bingener-Casey J, Tang CM, Sicklick JK, Gibbons SJ, Farrugia G, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Ramachandran A, Ordog T.

Gastroenterology. 2015 Aug;149(2):420-32.e16. doi: 10.1053/j.gastro.2015.04.006. Epub 2015 Apr 9.

5.

FAM96A is a novel pro-apoptotic tumor suppressor in gastrointestinal stromal tumors.

Schwamb B, Pick R, Fernández SB, Völp K, Heering J, Dötsch V, Bösser S, Jung J, Beinoraviciute-Kellner R, Wesely J, Zörnig I, Hammerschmidt M, Nowak M, Penzel R, Zatloukal K, Joos S, Rieker RJ, Agaimy A, Söder S, Reid-Lombardo KM, Kendrick ML, Bardsley MR, Hayashi Y, Asuzu DT, Syed SA, Ordog T, Zörnig M.

Int J Cancer. 2015 Sep 15;137(6):1318-29. doi: 10.1002/ijc.29498. Epub 2015 Mar 12.

PMID:
25716227
6.

Gastrointestinal stromal tumor - an evolving concept.

Tornillo L.

Front Med (Lausanne). 2014 Nov 11;1:43. doi: 10.3389/fmed.2014.00043. eCollection 2014. Review.

7.

microRNA expression signatures of gastrointestinal stromal tumours: associations with imatinib resistance and patient outcome.

Akçakaya P, Caramuta S, Åhlen J, Ghaderi M, Berglund E, Östman A, Bränström R, Larsson C, Lui WO.

Br J Cancer. 2014 Nov 25;111(11):2091-102. doi: 10.1038/bjc.2014.548. Epub 2014 Oct 30.

8.

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

Garner AP, Gozgit JM, Anjum R, Vodala S, Schrock A, Zhou T, Serrano C, Eilers G, Zhu M, Ketzer J, Wardwell S, Ning Y, Song Y, Kohlmann A, Wang F, Clackson T, Heinrich MC, Fletcher JA, Bauer S, Rivera VM.

Clin Cancer Res. 2014 Nov 15;20(22):5745-55. doi: 10.1158/1078-0432.CCR-14-1397. Epub 2014 Sep 19.

9.

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors.

Yeh CN, Yen CC, Chen YY, Cheng CT, Huang SC, Chang TW, Yao FY, Lin YC, Wen YS, Chiang KC, Chen JS, Yeh TS, Tzeng CH, Chao TC, Fletcher JA.

Oncotarget. 2014 Jun 30;5(12):4071-86.

10.

The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.

DeCaprio JA, Duensing A.

Curr Opin Oncol. 2014 Jul;26(4):415-21. doi: 10.1097/CCO.0000000000000090. Review.

11.

Recent advances in the treatment of gastrointestinal stromal tumors.

Serrano C, George S.

Ther Adv Med Oncol. 2014 May;6(3):115-27. doi: 10.1177/1758834014522491. Review.

12.

Phase I study of panobinostat and imatinib in patients with treatment-refractory metastatic gastrointestinal stromal tumors.

Bauer S, Hilger RA, Mühlenberg T, Grabellus F, Nagarajah J, Hoiczyk M, Reichardt A, Ahrens M, Reichardt P, Grunewald S, Scheulen ME, Pustowka A, Bock E, Schuler M, Pink D.

Br J Cancer. 2014 Mar 4;110(5):1155-62. doi: 10.1038/bjc.2013.826. Epub 2014 Jan 16.

13.

Membrane-to-nucleus signaling links insulin-like growth factor-1- and stem cell factor-activated pathways.

Hayashi Y, Asuzu DT, Gibbons SJ, Aarsvold KH, Bardsley MR, Lomberk GA, Mathison AJ, Kendrick ML, Shen KR, Taguchi T, Gupta A, Rubin BP, Fletcher JA, Farrugia G, Urrutia RA, Ordog T.

PLoS One. 2013 Oct 7;8(10):e76822. doi: 10.1371/journal.pone.0076822. eCollection 2013.

14.

Gastrointestinal stromal tumors: management of metastatic disease and emerging therapies.

Vadakara J, von Mehren M.

Hematol Oncol Clin North Am. 2013 Oct;27(5):905-20. doi: 10.1016/j.hoc.2013.07.007. Review.

15.

A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas.

Wagner AJ, Chugh R, Rosen LS, Morgan JA, George S, Gordon M, Dunbar J, Normant E, Grayzel D, Demetri GD.

Clin Cancer Res. 2013 Nov 1;19(21):6020-9. doi: 10.1158/1078-0432.CCR-13-0953. Epub 2013 Sep 17.

16.

Update on imatinib for gastrointestinal stromal tumors: duration of treatment.

Linch M, Claus J, Benson C.

Onco Targets Ther. 2013 Jul 30;6:1011-23. doi: 10.2147/OTT.S31260. Print 2013.

17.

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.

Kampa-Schittenhelm KM, Heinrich MC, Akmut F, Rasp KH, Illing B, Döhner H, Döhner K, Schittenhelm MM.

Mol Cancer. 2013 May 24;12:46. doi: 10.1186/1476-4598-12-46.

18.

The C-kit receptor-mediated signal transduction and tumor-related diseases.

Liang J, Wu YL, Chen BJ, Zhang W, Tanaka Y, Sugiyama H.

Int J Biol Sci. 2013 May 8;9(5):435-43. doi: 10.7150/ijbs.6087. Print 2013. Review.

19.

Genome-wide functional screening identifies CDC37 as a crucial HSP90-cofactor for KIT oncogenic expression in gastrointestinal stromal tumors.

Mariño-Enríquez A, Ou WB, Cowley G, Luo B, Jonker AH, Mayeda M, Okamoto M, Eilers G, Czaplinski JT, Sicinska E, Wang Y, Taguchi T, Demetri GD, Root DE, Fletcher JA.

Oncogene. 2014 Apr 3;33(14):1872-6. doi: 10.1038/onc.2013.127. Epub 2013 Apr 15.

20.

DOG1 regulates growth and IGFBP5 in gastrointestinal stromal tumors.

Simon S, Grabellus F, Ferrera L, Galietta L, Schwindenhammer B, Mühlenberg T, Taeger G, Eilers G, Treckmann J, Breitenbuecher F, Schuler M, Taguchi T, Fletcher JA, Bauer S.

Cancer Res. 2013 Jun 15;73(12):3661-70. doi: 10.1158/0008-5472.CAN-12-3839. Epub 2013 Apr 10.

Items per page

Supplemental Content

Write to the Help Desk